ECSP099518A - Uso de derivados de ácido de piranona sustituidos para el tratamiento del síndrome metabólico - Google Patents
Uso de derivados de ácido de piranona sustituidos para el tratamiento del síndrome metabólicoInfo
- Publication number
- ECSP099518A ECSP099518A EC2009009518A ECSP099518A ECSP099518A EC SP099518 A ECSP099518 A EC SP099518A EC 2009009518 A EC2009009518 A EC 2009009518A EC SP099518 A ECSP099518 A EC SP099518A EC SP099518 A ECSP099518 A EC SP099518A
- Authority
- EC
- Ecuador
- Prior art keywords
- metabolic syndrome
- piranone
- acid derivatives
- treatment
- derivatives replaced
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Abstract
La invención se refiere al uso de derivados de ácido de piranona sustituidos y de sus sales fisiológicamente aceptables para producir medicamentos para tratar el síndrome metabólico.Se describe el uso de compuesto de la fórmula I, Ien la cual los radicales tienen los significados dados, así como sus sales fisiológicamente aceptables para producir un medicamento para tratar el síndrome metabólico.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102007002260A DE102007002260A1 (de) | 2007-01-16 | 2007-01-16 | Verwendung von substituierten Pyranonsäurederivaten zur Herstellung von Medikamenten zur Behandlung des Metabolischen Syndroms |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP099518A true ECSP099518A (es) | 2009-08-28 |
Family
ID=39232744
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2009009518A ECSP099518A (es) | 2007-01-16 | 2009-07-15 | Uso de derivados de ácido de piranona sustituidos para el tratamiento del síndrome metabólico |
Country Status (31)
Country | Link |
---|---|
US (1) | US8748483B2 (es) |
EP (1) | EP2120923B1 (es) |
JP (1) | JP2010515765A (es) |
KR (1) | KR20090110834A (es) |
CN (1) | CN101600427A (es) |
AR (1) | AR064899A1 (es) |
AU (1) | AU2008207170A1 (es) |
BR (1) | BRPI0806661A2 (es) |
CA (1) | CA2675442A1 (es) |
CL (1) | CL2008000110A1 (es) |
CR (1) | CR10850A (es) |
CY (1) | CY1113148T1 (es) |
DE (1) | DE102007002260A1 (es) |
DK (1) | DK2120923T3 (es) |
DO (1) | DOP2009000177A (es) |
EC (1) | ECSP099518A (es) |
ES (1) | ES2390513T3 (es) |
HR (1) | HRP20120763T1 (es) |
IL (1) | IL199829A0 (es) |
MA (1) | MA31094B1 (es) |
MX (1) | MX2009006913A (es) |
PE (1) | PE20081700A1 (es) |
PL (1) | PL2120923T3 (es) |
PT (1) | PT2120923E (es) |
RS (1) | RS52494B (es) |
RU (1) | RU2009131058A (es) |
SI (1) | SI2120923T1 (es) |
TN (1) | TN2009000275A1 (es) |
TW (1) | TW200836716A (es) |
UY (1) | UY30871A1 (es) |
WO (1) | WO2008086949A1 (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2011157827A1 (de) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
JP2016502982A (ja) * | 2012-12-13 | 2016-02-01 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | タンパク質接着性の活性物質としての3−ヒドロキシ−4−オキソ−4h−ピランまたは3−ヒドロキシ−4−オキソ−1,4−ジヒドロピリジンの誘導体 |
JP6338276B2 (ja) * | 2014-07-10 | 2018-06-06 | 学校法人神奈川大学 | 抗癌剤 |
CN116322544A (zh) | 2020-08-12 | 2023-06-23 | 云杉生物科学公司 | 用于治疗***的方法和组合物 |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3152148A (en) | 1963-01-03 | 1964-10-06 | Dow Chemical Co | Preparation of comenic and pyromeconic acids |
DE2966702D1 (en) | 1978-06-26 | 1984-03-29 | Measurex Corp | Method and apparatus for measuring gas, including standardisation |
JPS59125644A (ja) | 1982-12-29 | 1984-07-20 | Fujitsu Ltd | 半導体装置 |
US4603144A (en) | 1984-08-16 | 1986-07-29 | G. D. Searle & Co. | Kojic acid ether-ester derivatives |
GB8615041D0 (en) * | 1986-06-20 | 1986-07-23 | Silver J | Pharmaceutical compositions |
DE3728602A1 (de) | 1987-08-27 | 1989-03-09 | Bayer Ag | Faserverstaerktes polyphenylensulfid |
DE3728924A1 (de) | 1987-08-29 | 1989-03-09 | Bayer Ag | Flammwidrige, thermoplastische formmassen auf basis von polycarbonat, polyalkylenterephthalat, pfropfcopolymerisat, fluoriertem polyolefin und phosphorverbindung |
DE3729586A1 (de) | 1987-09-04 | 1989-03-16 | Ant Nachrichtentech | Verfahren zum ausgleichen von durch den doppler-effekt hervorgerufenen laufzeit-verschiebungen der bursts in einem tdma-rahmen sowie anordnung |
CA2007414C (en) | 1989-04-26 | 1994-10-25 | Clayton James Bennett Iii | Method for manipulating elements within a structured document using active intent interpretations |
FR2663336B1 (fr) | 1990-06-18 | 1992-09-04 | Adir | Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
JPH06271500A (ja) * | 1993-03-23 | 1994-09-27 | Noguchi Kenkyusho | コマン酸の製造法 |
DE19530298C2 (de) * | 1995-08-17 | 1999-07-22 | Woerwag Pharma Gmbh | Verwendung von Orotsäure zur Prävention und Therapie des metabolischen Syndroms |
KR19990077319A (ko) | 1996-01-17 | 1999-10-25 | 한센 핀 베네드, 안네 제헤르 | 축합된 1,2,4-티아디아진 및 축합된 1,4-티아진 유도체, 그것의제조방법 및 사용 |
UA51716C2 (uk) | 1996-07-08 | 2002-12-16 | Авентіс Фармасьютікалз Продактс Інк. | Сполуки, що мають гіпотензивну, кардіопротекторну, анти-ішемічну та антиліполітичну властивості, фармацевтична композиція та способи лікування |
ATE356830T1 (de) | 1996-08-30 | 2007-04-15 | Novo Nordisk As | Glp-1 derivate |
PL192664B1 (pl) | 1996-12-31 | 2006-11-30 | Reddys Lab Ltd Dr | Pochodne azolidynodionu, sposób ich wytwarzania, zawierające je kompozycje farmaceutyczne, ich zastosowanie w leczeniu cukrzycy i związanych z nią chorób oraz związki pośrednie |
DE19726167B4 (de) | 1997-06-20 | 2008-01-24 | Sanofi-Aventis Deutschland Gmbh | Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung |
PL338013A1 (en) | 1997-07-16 | 2000-09-25 | Novo Nordisk As | Derivatives of condensed 1,2,4-thiadiazine, their production and application |
CO4970713A1 (es) | 1997-09-19 | 2000-11-07 | Sanofi Synthelabo | Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen |
US6221897B1 (en) | 1998-06-10 | 2001-04-24 | Aventis Pharma Deutschland Gmbh | Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use |
DE19845405C2 (de) | 1998-10-02 | 2000-07-13 | Aventis Pharma Gmbh | Arylsubstituierte Propanolaminderivate und deren Verwendung |
GB9900416D0 (en) | 1999-01-08 | 1999-02-24 | Alizyme Therapeutics Ltd | Inhibitors |
WO2000063208A1 (en) | 1999-04-16 | 2000-10-26 | Novo Nordisk A/S | Substituted imidazoles, their preparation and use |
EE200100556A (et) | 1999-04-28 | 2003-02-17 | Aventis Pharma Deutschland Gmbh | Diarüülhappe derivaat, seda sisaldav farmatseutiline kompositsioon ja ühendi kasutamine ravimite valmistamiseks |
AU782404B2 (en) | 1999-04-28 | 2005-07-28 | Sanofi-Aventis Deutschland Gmbh | Tri-aryl acid derivatives as PPAR receptor ligands |
AU4808300A (en) | 1999-04-30 | 2000-11-17 | Neurogen Corporation | 9h-pyrimido(4,5-b)indole derivatives: crf1 specific ligands |
GB9911863D0 (en) | 1999-05-21 | 1999-07-21 | Knoll Ag | Therapeutic agents |
US6399640B1 (en) | 1999-06-18 | 2002-06-04 | Merck & Co., Inc. | Arylthiazolidinedione and aryloxazolidinedione derivatives |
CA2378878A1 (en) | 1999-07-29 | 2001-02-08 | Jeffrey Thomas Mullaney | Benzofurylpiperazines and benzofurylhomopiperazines: serotonin agonists |
IL148148A0 (en) | 1999-09-01 | 2002-09-12 | Aventis Pharma Gmbh | Sulfonyl carboxamide derivatives, method for their production and their use as medicaments |
KR100502876B1 (ko) | 2000-04-28 | 2005-07-21 | 아사히 가세이 파마 가부시키가이샤 | 신규 이환성 화합물 |
ES2252230T3 (es) | 2000-05-11 | 2006-05-16 | Bristol-Myers Squibb Company | Analogos de tetrahidroisoquinolina utiles como secretores de la hormona del crecimiento. |
WO2001091752A1 (en) | 2000-05-30 | 2001-12-06 | Merck & Co., Inc. | Melanocortin receptor agonists |
DE10033353A1 (de) | 2000-07-08 | 2002-01-24 | Aventis Pharma Gmbh | Breit einsetzbares Verfahren zur Identifizierung von Modulatoren von G-Protein gekoppelten Rezeptoren |
FR2814678B1 (fr) | 2000-10-04 | 2002-12-20 | Aventis Pharma Sa | Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite |
IL156552A0 (en) | 2000-12-21 | 2004-01-04 | Aventis Pharma Gmbh | Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use |
EP1425014B1 (de) | 2001-08-31 | 2006-12-13 | Sanofi-Aventis Deutschland GmbH | Diarylcycloalkylderivate, verfahren zu ihrer herstellung und ihre verwendung als ppar-aktivatoren |
US6552073B1 (en) | 2002-03-01 | 2003-04-22 | Exonhit Therapeutics Sa | Compounds and methods of treating cell proliferative diseases |
DE10227507A1 (de) | 2002-06-19 | 2004-01-08 | Aventis Pharma Deutschland Gmbh | Kationisch substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
DE10227506A1 (de) | 2002-06-19 | 2004-01-08 | Aventis Pharma Deutschland Gmbh | Ringsubstituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
DE10227508A1 (de) | 2002-06-19 | 2004-01-08 | Aventis Pharma Deutschland Gmbh | Säuregruppen-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
DE10307004B3 (de) | 2003-02-19 | 2004-08-05 | Siemens Ag | Verfahren zur Steuerung einer Brennkraftmaschine mit einer Lambda-Regelung |
-
2007
- 2007-01-16 DE DE102007002260A patent/DE102007002260A1/de not_active Withdrawn
-
2008
- 2008-01-04 SI SI200830757T patent/SI2120923T1/sl unknown
- 2008-01-04 BR BRPI0806661-2A patent/BRPI0806661A2/pt not_active IP Right Cessation
- 2008-01-04 EP EP08700981A patent/EP2120923B1/de active Active
- 2008-01-04 ES ES08700981T patent/ES2390513T3/es active Active
- 2008-01-04 KR KR1020097014783A patent/KR20090110834A/ko not_active Application Discontinuation
- 2008-01-04 WO PCT/EP2008/000029 patent/WO2008086949A1/de active Application Filing
- 2008-01-04 AU AU2008207170A patent/AU2008207170A1/en not_active Abandoned
- 2008-01-04 CN CNA2008800023932A patent/CN101600427A/zh active Pending
- 2008-01-04 MX MX2009006913A patent/MX2009006913A/es not_active Application Discontinuation
- 2008-01-04 PT PT08700981T patent/PT2120923E/pt unknown
- 2008-01-04 PL PL08700981T patent/PL2120923T3/pl unknown
- 2008-01-04 RS RS20120437A patent/RS52494B/en unknown
- 2008-01-04 DK DK08700981.7T patent/DK2120923T3/da active
- 2008-01-04 RU RU2009131058/15A patent/RU2009131058A/ru unknown
- 2008-01-04 CA CA002675442A patent/CA2675442A1/en not_active Abandoned
- 2008-01-04 JP JP2009545849A patent/JP2010515765A/ja not_active Withdrawn
- 2008-01-14 PE PE2008000138A patent/PE20081700A1/es not_active Application Discontinuation
- 2008-01-14 AR ARP080100165A patent/AR064899A1/es not_active Application Discontinuation
- 2008-01-14 TW TW097101284A patent/TW200836716A/zh unknown
- 2008-01-14 UY UY30871A patent/UY30871A1/es not_active Application Discontinuation
- 2008-01-15 CL CL200800110A patent/CL2008000110A1/es unknown
-
2009
- 2009-06-09 CR CR10850A patent/CR10850A/es not_active Application Discontinuation
- 2009-06-26 TN TNP2009000275A patent/TN2009000275A1/fr unknown
- 2009-07-13 IL IL199829A patent/IL199829A0/en unknown
- 2009-07-13 DO DO2009000177A patent/DOP2009000177A/es unknown
- 2009-07-14 MA MA32090A patent/MA31094B1/fr unknown
- 2009-07-15 EC EC2009009518A patent/ECSP099518A/es unknown
- 2009-07-16 US US12/504,198 patent/US8748483B2/en not_active Expired - Fee Related
-
2012
- 2012-09-26 HR HRP20120763AT patent/HRP20120763T1/hr unknown
- 2012-09-27 CY CY20121100882T patent/CY1113148T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
DE102007002260A1 (de) | 2008-07-31 |
DOP2009000177A (es) | 2009-08-15 |
RU2009131058A (ru) | 2011-02-27 |
SI2120923T1 (sl) | 2012-10-30 |
TN2009000275A1 (en) | 2010-10-18 |
HRP20120763T1 (hr) | 2012-10-31 |
WO2008086949A1 (de) | 2008-07-24 |
DK2120923T3 (da) | 2012-10-29 |
CR10850A (es) | 2009-10-16 |
AU2008207170A1 (en) | 2008-07-24 |
CL2008000110A1 (es) | 2008-05-16 |
ES2390513T3 (es) | 2012-11-13 |
US8748483B2 (en) | 2014-06-10 |
RS52494B (en) | 2013-02-28 |
MA31094B1 (fr) | 2010-01-04 |
AR064899A1 (es) | 2009-05-06 |
KR20090110834A (ko) | 2009-10-22 |
MX2009006913A (es) | 2009-08-12 |
EP2120923B1 (de) | 2012-07-18 |
IL199829A0 (en) | 2010-04-15 |
PE20081700A1 (es) | 2009-01-08 |
BRPI0806661A2 (pt) | 2011-09-06 |
EP2120923A1 (de) | 2009-11-25 |
TW200836716A (en) | 2008-09-16 |
JP2010515765A (ja) | 2010-05-13 |
CN101600427A (zh) | 2009-12-09 |
PT2120923E (pt) | 2012-08-31 |
CA2675442A1 (en) | 2008-07-24 |
CY1113148T1 (el) | 2016-04-13 |
PL2120923T3 (pl) | 2012-12-31 |
US20100144862A1 (en) | 2010-06-10 |
UY30871A1 (es) | 2008-09-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP099518A (es) | Uso de derivados de ácido de piranona sustituidos para el tratamiento del síndrome metabólico | |
CY1120832T1 (el) | Τροποποιητες πυρηνικης μεταφορας και χρησεις αυτων | |
CY1124000T1 (el) | Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες σε κρυσταλλικη μορφη | |
ECSP088747A (es) | Pirazoles como inhibidores de la 11-beta-hsd1 | |
ECSP14013199A (es) | Compuestos para el tratamiento y profilaxis de la enfermedad del virus sincicial respiratorio | |
UY32848A (es) | Compuestos heterocíclicos de oxima | |
CR11757A (es) | Compuestos de triazina como inhibidores mtor y quinasa pi3 | |
CO6300957A2 (es) | Derivados de imidazo -[1,2,b]-piridazina para el tratamiento de enfermedad mediada por cinasa de tirosina c-met | |
BR112015026023A2 (pt) | derivados de 2- aminopirido[4,3-d]pirimidin-5-ona e seu uso como inibidores de wee-1 | |
EA201100136A1 (ru) | 2,4'-бипиридинилы в качестве ингибиторов протеинкиназы d, применимые для лечения сердечной недостаточности и рака | |
CO6612228A2 (es) | Inhibidores de jak2 y su uso en el tratamiento de enfermedades mieloproliferativas y cancer | |
UY32585A (es) | Nuevos derivados del indazol utiles como inhibidores de la familia fosfoinositida 3´oh quinasa | |
ECSP12012065A (es) | Derivados de pirazina y su uso en el tratamiento de trastornos neurológicos | |
CU24335B1 (es) | Piridopirimidinas sustituidas como inhibidores de la quinasa mek y útiles para el tratamiento del cáncer | |
ECSP13012417A (es) | Derivados de ácido napht-2-ilacético para tratar sida | |
EA201491060A1 (ru) | Новые производные трифторметилоксадиазола и их применение для лечения заболевания | |
GT201400131A (es) | Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina | |
CO6781507A2 (es) | Novedosos derivados heterociclicos | |
CO6491060A2 (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
CO6480932A2 (es) | Antagonistas de la trayectoria hedgehog de ftalazina disustituida. | |
EA201200260A1 (ru) | Гетероциклические гидразоны и их применение для лечения рака и воспаления | |
CO6361924A2 (es) | Nuevas lactamas como inhibidores de beta secretasa | |
CL2019002900A1 (es) | Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton. | |
AR079945A1 (es) | Derivados de pirazina como inhibidores de glucogeno sintasa quinasa 3 (gsk3) | |
EA201490630A1 (ru) | 6-замещенные 3-(хинолин-6-илтио)[1,2,4]триазоло[4,3-a]пиридины в качестве ингибиторов c-met тирозинкиназы |